Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide

Endocrine-Related Cancer

Volumn 21, Issue 5, 2014, Pages 705-714

  Kulke, Matthew H ^f   O'Dorisio, Thomas ^a   Phan, Alexandria ^b   Bergsland, Emily ^c   Law, Linda ^d   Banks, Phillip ^d   Freiman, Joel ^d   Frazier, Kenny ^d   Jackson, Jessica ^d   Yao, James C ^b   Kvols, Larry ^e   Lapuerta, Pablo ^d   Zambrowicz, Brian ^d   Fleming, Douglas ^d   Sands, Arthur ^d  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LEXICON PHARMACEUTICALS INC   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Adult; Carcinoid syndrome; Diarrhea; Neuroendocrine tumor; Serotonin; Tryptophan hydroxylase

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GASTROINTESTINAL AGENT; OCTREOTIDE; PHENYLALANINE; PYRIMIDINE DERIVATIVE; SEROTONIN ANTAGONIST; TELOTRISTAT;

ADULT; AGED; ANALOGS AND DERIVATIVES; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; MALE; MALIGNANT CARCINOID SYNDROME; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; DIARRHEA; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; MALIGNANT CARCINOID SYNDROME; MIDDLE AGED; OCTREOTIDE; PHENYLALANINE; PYRIMIDINES; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 84907485329     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0173     Document Type: Article

References (15)

1. Beaumont JL, Cella D, Phan AT, Choi S, Liu Z & Yao JC 2012 Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas 41 461-466. (doi:10.1097/MPA.0b013e3182328045)
2. Centers for Disease Control and Prevention (CDC) 1997 Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR. Morbidity and Mortality Weekly Report 46 1061-1066.
3. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD & Schaff HV 1997 Valvular heart disease associated with fenfluramine-phentermine. New England Journal of Medicine 337 581-588
4. (Erratum in: New England Journal of Medicine 1997 Dec 11; 337(24) 1783). (doi:10.1056/NEJM199708283370901)
5. Creutzfeldt W 1996 Carcinoid tumors: development of our knowledge. World Journal of Surgery 20 126-131. (doi:10.1007/s002689900020)
6. Dobson R, Burgess MI, Banks M, Pritchard DM, Vora J, Valle JW, Wong C, Chadwick C, George K, Keevil B et al. 2013 The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study. PLoS ONE 8 e73679. (doi:10.1371/journal.pone.0073679)
7. Druce M, Rockall A & Grossman AB 2009 Fibrosis and carcinoid syndrome: from causation to future therapy. Nature Reviews. Endocrinology 5 276-283. (doi:10.1038/nrendo.2009.51)
8. Engelman K, Lovenberg W & Sjoerdsma A 1967 Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome. New England Journal of Medicine 277 1103-1108. (doi:10.1056/NEJM196711232772101)
9. Gustafsson BI, Tommeras K, Nordrum I, Loennechen JP, Brunsvik A, Solligard E, Fossmark R, Bakke I, Syversen U & Waldum H 2005 Long-term serotonin administration induces heart valve disease in rats. Circulation 111 1517-1522. (doi:10.1161/01.CIR.0000159356.42064.48)
10. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J & Hahn RG 1986 Treatment of the malignant carcinoid syndrome. Evaluation of a longacting somatostatin analogue. New England Journal of Medicine 315 663-666. (doi:10.1056/NEJM198609113151102)
11. Kvols L, Oberg KE, O'Dorisio T, Mohideen P, de Herder WW, Arnold R, Hu K, Zhang Y, Hughes G, Anthony L et al. 2012 Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocrine-Related Cancer 19 657-666. (doi:10.1530/ERC-11-0367)
12. Lexicon Pharmaceuticals 2007 Lexicon in-house Report Number P103-002: Pharmacology of LX1606 (final report date 30 November 2007). The Woodlands, TX, USA: Lexicon Pharmaceuticals.
13. Lexicon Pharmaceuticals 2012 Lexicon in-house LX1606.1-202 Clinical Study Report: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Ascending, Multi-dose Study to Determine the Safety and Tolerability of Orally Administered LX1606 in Subjects with Symptomatic Carcinoid Syndrome Refractory to Stable-dose Octreotide Long-acting Release Depot Therapy (final report date 01 May 2012). The Woodlands, TX, USA: Lexicon Pharmaceuticals.
14. Melmon KL, Sjoerdsma A, Oates JA & Laster L 1965 Treatment of malabsorption and diarrhea of the carcinoid syndrome with methysergide. Gastroenterology 48 18-24.
15. Moler JE, Connolly HM, Rubin J, Seward JB, Modesto K & Pellikka PA 2003 Factors associated with progression of carcinoid heart disease. New England Journal of Medicine 348 1005-1015. (doi:10.1056/NEJMoa021451)